Sees Q2 Revenue of $55M-$56M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Should l Buy DH?
Sees Q2 revenue $55M-$56M, consensus $55.47M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DH
Wall Street analysts forecast DH stock price to rise
9 Analyst Rating
3 Buy
5 Hold
1 Sell
Hold
Current: 0.886
Low
2.75
Averages
3.71
High
5.00
Current: 0.886
Low
2.75
Averages
3.71
High
5.00
About DH
Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. Its business is conducted through AIDH TopCo, LLC (Definitive OpCo).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Definitive Healthcare Corp. Q1 2026 Earnings Call Insights
- Revenue and Profit Performance: Definitive Healthcare reported total revenue of $55.9 million in Q1, a 6% year-over-year decline; however, adjusted EBITDA reached $15.3 million, reflecting a 27% margin, exceeding guidance by $2.3 million, indicating effective cost management.
- Cash Flow and Business Growth: The company generated approximately $50 million of unlevered free cash flow over the past 12 months, and despite a decline in Life Sciences, the Diversified and Provider segments, which account for over 60% of total revenue, demonstrated resilience and modest growth.
- Integration and Innovation Progress: In Q1, nearly 50 new customer integrations were completed, with integration time reduced by nearly 50% year-over-year, while the company expects to launch its first AI-enabled solutions later this quarter, showcasing its commitment to technological innovation.
- Future Outlook and Guidance: The company anticipates total revenue of $55 million to $56 million for Q2, with adjusted EBITDA projected between $13.5 million and $14.5 million, and full-year revenue guidance set at $220 million to $226 million, reflecting management's confidence in future growth.
See More
Definitive Healthcare Q1 Earnings Report Analysis
- Earnings Performance: Definitive Healthcare reported a Q1 GAAP EPS of -$1.32, missing expectations by $1.25, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $55.9M, exceeding expectations by $0.92M, suggesting an improvement in market demand, although overall profitability remains a concern.
- Future Outlook: For Q2, revenue is expected to range between $55.0M and $56.0M, with adjusted operating income projected at $10.5M to $11.5M, reflecting a cautiously optimistic view on future growth.
- Annual Forecast: For the full year 2026, revenue is anticipated to be between $220.0M and $226.0M, with adjusted net income expected to be $23.0M to $27.0M, demonstrating the company's ongoing commitment to long-term growth strategies.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
- RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
- Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
- Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
See More
Definitive Healthcare Q4 Earnings Report Analysis
- Earnings Performance: Definitive Healthcare reported a Q4 GAAP EPS of -$0.09, missing the expected -$0.06, indicating ongoing profitability pressures that could undermine investor confidence.
- Revenue Details: The company posted revenues of $61.5 million, a 1.3% year-over-year decline, although it slightly exceeded expectations of $61.31 million; however, the ongoing revenue decline poses challenges for future growth prospects.
- Market Reaction: Given the earnings miss, market reactions to the company's stock may lean negative, prompting investors to closely monitor subsequent strategic adjustments and market adaptability.
- Future Outlook: Despite slightly surpassing revenue expectations, the persistent losses and declining revenues may compel management to reassess its business strategy to restore market confidence and drive long-term growth.
See More
Advent International Invests $2.35 Billion to Make NIQ Its Leading Investment
Advent International's Investment: Boston-based Advent International has acquired a new stake in NIQ Global Intelligence plc, purchasing 149,380,246 shares valued at approximately $2.35 billion, making it the fund's largest holding.
Financial Overview of NIQ: As of September 30, 2025, NIQ reported trailing twelve months revenue of $4.01 billion and a net loss of $434.36 million, with shares priced at $14.18, which is 30.46% below its 52-week high.
NIQ's Market Position: NIQ operates globally with over 38,000 employees, providing an AI-powered consumer intelligence platform that analyzes shopping data to deliver insights for brands and retailers, playing a crucial role in consumer behavior analysis.
Investment Implications: Advent's significant investment suggests confidence in NIQ's long-term value despite current market pressures, as the company seeks to convert its data capabilities into consistent free cash flow while managing its debt load.
See More
De Havilland Partners with Avincis to Enhance CL Series Aircraft Services
- Collaboration Agreement: De Havilland and Avincis have established a partnership where Avincis transfers its ADS-B and FMS supplemental type certificates for CL aircraft to De Havilland, enhancing the spare parts catalog and improving access to critical system solutions for global CL aircraft operators.
- Market Responsiveness: This collaboration enables De Havilland to better serve Avincis, the largest operator of CL-415 aircraft globally, which is expected to enhance customer satisfaction and strengthen market competitiveness.
- Design and Maintenance Capabilities: Avincis brings over 20 years of operational experience with CL-415 aircraft, providing robust design and maintenance capabilities that will deliver high-quality solutions to global CL aircraft operators, further solidifying its market position.
- Commitment to Ongoing Investment: This partnership is part of De Havilland's ongoing investment and commitment to CL aircraft customers, demonstrating the company's dedication to enhancing its service capabilities in the global aviation market through collaboration with Avincis.
See More
Definitive Healthcare Corp. Q1 2026 Earnings Call Insights
- Revenue and Profit Performance: Definitive Healthcare reported total revenue of $55.9 million in Q1, a 6% year-over-year decline; however, adjusted EBITDA reached $15.3 million, reflecting a 27% margin, exceeding guidance by $2.3 million, indicating effective cost management.
- Cash Flow and Business Growth: The company generated approximately $50 million of unlevered free cash flow over the past 12 months, and despite a decline in Life Sciences, the Diversified and Provider segments, which account for over 60% of total revenue, demonstrated resilience and modest growth.
- Integration and Innovation Progress: In Q1, nearly 50 new customer integrations were completed, with integration time reduced by nearly 50% year-over-year, while the company expects to launch its first AI-enabled solutions later this quarter, showcasing its commitment to technological innovation.
- Future Outlook and Guidance: The company anticipates total revenue of $55 million to $56 million for Q2, with adjusted EBITDA projected between $13.5 million and $14.5 million, and full-year revenue guidance set at $220 million to $226 million, reflecting management's confidence in future growth.
See More
Definitive Healthcare Q1 Earnings Report Analysis
- Earnings Performance: Definitive Healthcare reported a Q1 GAAP EPS of -$1.32, missing expectations by $1.25, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $55.9M, exceeding expectations by $0.92M, suggesting an improvement in market demand, although overall profitability remains a concern.
- Future Outlook: For Q2, revenue is expected to range between $55.0M and $56.0M, with adjusted operating income projected at $10.5M to $11.5M, reflecting a cautiously optimistic view on future growth.
- Annual Forecast: For the full year 2026, revenue is anticipated to be between $220.0M and $226.0M, with adjusted net income expected to be $23.0M to $27.0M, demonstrating the company's ongoing commitment to long-term growth strategies.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
- RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
- Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
- Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
See More
Definitive Healthcare Q4 Earnings Report Analysis
- Earnings Performance: Definitive Healthcare reported a Q4 GAAP EPS of -$0.09, missing the expected -$0.06, indicating ongoing profitability pressures that could undermine investor confidence.
- Revenue Details: The company posted revenues of $61.5 million, a 1.3% year-over-year decline, although it slightly exceeded expectations of $61.31 million; however, the ongoing revenue decline poses challenges for future growth prospects.
- Market Reaction: Given the earnings miss, market reactions to the company's stock may lean negative, prompting investors to closely monitor subsequent strategic adjustments and market adaptability.
- Future Outlook: Despite slightly surpassing revenue expectations, the persistent losses and declining revenues may compel management to reassess its business strategy to restore market confidence and drive long-term growth.
See More
Advent International Invests $2.35 Billion to Make NIQ Its Leading Investment
Advent International's Investment: Boston-based Advent International has acquired a new stake in NIQ Global Intelligence plc, purchasing 149,380,246 shares valued at approximately $2.35 billion, making it the fund's largest holding.
Financial Overview of NIQ: As of September 30, 2025, NIQ reported trailing twelve months revenue of $4.01 billion and a net loss of $434.36 million, with shares priced at $14.18, which is 30.46% below its 52-week high.
NIQ's Market Position: NIQ operates globally with over 38,000 employees, providing an AI-powered consumer intelligence platform that analyzes shopping data to deliver insights for brands and retailers, playing a crucial role in consumer behavior analysis.
Investment Implications: Advent's significant investment suggests confidence in NIQ's long-term value despite current market pressures, as the company seeks to convert its data capabilities into consistent free cash flow while managing its debt load.
See More
De Havilland Partners with Avincis to Enhance CL Series Aircraft Services
- Collaboration Agreement: De Havilland and Avincis have established a partnership where Avincis transfers its ADS-B and FMS supplemental type certificates for CL aircraft to De Havilland, enhancing the spare parts catalog and improving access to critical system solutions for global CL aircraft operators.
- Market Responsiveness: This collaboration enables De Havilland to better serve Avincis, the largest operator of CL-415 aircraft globally, which is expected to enhance customer satisfaction and strengthen market competitiveness.
- Design and Maintenance Capabilities: Avincis brings over 20 years of operational experience with CL-415 aircraft, providing robust design and maintenance capabilities that will deliver high-quality solutions to global CL aircraft operators, further solidifying its market position.
- Commitment to Ongoing Investment: This partnership is part of De Havilland's ongoing investment and commitment to CL aircraft customers, demonstrating the company's dedication to enhancing its service capabilities in the global aviation market through collaboration with Avincis.
See More
